PS100 Conjugated.

The phosphatidylserine pool in neuronal membranes carries docosahexaenoic acid at the sn-2 position, and DHA availability drives serine incorporation into that pool. Supplying both gives the membrane the headgroup and the acyl chain it actually uses.

Phosphatidylserine is made in cells by swapping serine onto an existing phosphatidylcholine or phosphatidylethanolamine backbone. The two phospholipids sit on one interconverting pathway rather than two separate ones.

Decarboxylation of phosphatidylserine feeds phosphatidylethanolamine, which can be methylated onward toward phosphatidylcholine. Choline supply keeps that traffic from pulling on the serine-containing pool.

Alpha-GPC delivers choline for acetylcholine synthesis and is itself a phospholipid breakdown product that feeds back into membrane assembly. Phosphatidylserine is a headgroup product of that same membrane phospholipid traffic.

Citicoline is the activated intermediate that donates its headgroup during phospholipid assembly. Phosphatidylserine is one of the products of that same membrane-building traffic.

Long-chain omega-3 fatty acids are esterified into phospholipid rather than circulating free. Pairing them with a serine headgroup source targets both halves of the same membrane molecule.

Phosphatidylserine modulates the sensitivity of the hypothalamic pituitary adrenal feedback loop to cortisol, and ashwagandha withanolides act on the same stress axis from a different angle. They are combined for that overlap rather than for an additive receptor effect.

Phosphatidylserine is defined by its serine head group, which mammalian phosphatidylserine synthases attach by exchanging serine for the choline or ethanolamine head of an existing phospholipid. Serine supply is therefore upstream of the whole molecule. That is a biosynthetic relationship and not a claim that added serine raises brain phosphatidylserine.

Phosphatidic acid is the branch point of glycerophospholipid synthesis, converted to CDP-diacylglycerol and from there to phosphatidylserine. It sits two steps above the finished molecule in the pathway. The link is pathway position, established biochemistry, not a measured combination effect.

Membrane phospholipid synthesis runs through CDP-activated intermediates, and uridine feeds the pyrimidine nucleotide pool those intermediates draw on. That places uridine alongside choline and the long-chain fatty acids in the same membrane-building sequence. The pathway is settled; the effect of supplying uridine on membrane phospholipid content in adults is a separate question.

Serine hydroxymethyltransferase moves a one-carbon unit from serine to tetrahydrofolate, tying serine availability directly to folate status and running in both directions. So folate status shapes the size of the serine pool that phosphatidylserine synthesis draws on. This is enzyme-level coupling, not an outcome measured in a trial.

Glycine and serine convert into one another through the same folate-dependent enzyme, so the two amino acids share one metabolic pool. Pulling on that pool for glycine changes what is left for the phosphatidylserine head group, and the same holds in the other direction. Read this as pool sharing rather than a benefit claim.

Serine hydroxymethyltransferase and serine palmitoyltransferase both require pyridoxal 5-phosphate, so B6 status governs how serine is partitioned between one-carbon metabolism, sphingolipid synthesis and phospholipid head groups. B6 is upstream of the substrate, not of the phospholipid itself. Cofactor dependency, established at the enzyme level.

B12 is required by methionine synthase, and when that step slows folate is trapped in its methyl form, which constrains the serine-to-glycine reaction that shares the serine pool. The connection to phosphatidylserine runs through substrate supply. It is pathway coupling and not a measured combination.

The activation steps in phospholipid synthesis consume CTP and ATP, and those nucleotides work as magnesium complexes at the enzyme active site. Magnesium is therefore a general requirement of the pathway rather than anything specific to this phospholipid. No combination study is claimed.

Phosphatidylserine preparations, and particularly those carrying long-chain polyunsaturated fatty acids, are chemically vulnerable to peroxidation, and alpha-tocopherol is the chain-breaking antioxidant that limits it in a lipid phase. That matters for the ingredient in the bottle as well as in the membrane. The rationale is stability chemistry, not a cognitive claim.

Commercial phosphatidylserine is made from lecithin, with phospholipase D swapping the head group of phosphatidylcholine for serine, and sunflower lecithin is the non-soy feedstock used for that conversion. Residual lecithin phospholipids commonly remain in the finished ingredient. This is a manufacturing and matrix relationship rather than a physiological synergy.

Lecithin is the phospholipid mixture that supplies the phosphatidylcholine backbone converted into phosphatidylserine, and it is also a routine emulsifier in the finished softgel. So it appears both as feedstock and as excipient. Neither role is a claim about what the pair does in the body.

Caffeine acts as an adenosine receptor antagonist, a mechanism with no overlap with membrane phospholipid composition. The two are combined in attention and pre-workout products by formulation choice. Nothing in this material tested them together.

L-theanine is the usual partner for caffeine in attention formulas and travels with phosphatidylserine into the same products. The pairing is commercial rather than mechanistic. No combination evidence is offered here.

Ginkgo is combined with phosphatidylserine in older memory formulas, and one commercial ingredient historically bound the two together. Ginkgo also carries a platelet effect that matters when other platelet-active ingredients are in the same stack. No combination data appear in this material.

Huperzine A inhibits acetylcholinesterase, a distinct mechanism from supplying a membrane phospholipid, and the two are commonly stacked in nootropic products. Combining a cholinesterase inhibitor with choline donors raises cholinergic load, which is worth flagging. No combination study is available here.

Acetyl-L-carnitine supplies acetyl groups and supports mitochondrial fatty acid transport, which touches the lipid economy of the cell from a different direction than a phospholipid head group does. The two co-occur in the same product category. The pairing is not tested in this material.

Rhodiola is placed in stress-response formulas alongside phosphatidylserine because both are marketed to the same audience. No shared mechanism links a botanical extract to membrane phospholipid composition. Formulation logic only.